|drug3676||Vitamin D Wiki||0.35|
|drug3674||Vitamin C Wiki||0.28|
|D003141||Communicable Diseases NIH||0.08|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
High-throughput screening studies identified Abl kinase inhibitors (including imatinib) as inhibitors of coronaviruses SARS and MERS. The SARS-CoV-2 coronavirus depend on Abl2 kinase activity to fuse and enter into the cells. Pharmacokinetic studies demonstrated that IC50 of imatinib for ABL1, BCR-ABL1 and ABL2 kinase inhibition is less than 1 microM (around 0.3 microM) below the expected trough plasmatic concentrations of imatinib 400 mg/day (1.7 microM). The EC50 of imatinib for the inhibition of the virus is under investigation but we now have a first estimates with EC50 close to 2.5 microM. This plasmatic concentration is achievable with imatinib 800 mg/d. We hypothesize that clinically achievable imatinib concentration will block the first round of cell to cell virus infection and therefore stop or prevent from SARS-CoV-2 infection in human. Based on our 20 years' experience of prescribing imatinib in patients, we expect that most of the adverse events and pharmacological interactions of imatinib can be anticipated and corrected. The eligible population will be aged (>70y) patients hospitalized for a non-severe COVID-19 disease for less than 7 days. Patients will be randomized 1/1 between standard of care and imatinib 800 mg per day during 14 days. The primary endpoint will be the death rate by 30 days. Secondary endpoint will include progression to severe CIVID-19 disease, safety, outcome at 3 months. We plan to randomize 90 patients in order to show a 10% benefit in term of death rate reduction from 16% to 6%.
Description: To evaluate the 30 days mortality rate in aged patients hospitalized with COVID-19Measure: To evaluate the benefit of early imatinib therapy to prevent severe COVID-19 disease in hospitalized aged patients. Time: 30 days
Description: Drop out rate of imatinib mesylate therapyMeasure: To evaluate the feasibility of imatinib therapy. Time: Day 14
Description: Adverse events related to imatinib mesylate therapyMeasure: To evaluate safety of imatinib therapy Time: 3 months
Description: Clinical (WHO COVID scale) and geriatric scores (GIR, ADL and IADL) modificationMeasure: To evaluate the clinical evolution Time: 3 months
Description: Clinical (WHO COVID scale) and geriatric scores (GIR, ADL and IADL) modificationMeasure: To evaluate the progression rate to severe COVID-19 disease Time: 3 months
Description: number of deathMeasure: To evaluate mortality Time: 14 days
Description: number of deathMeasure: To evaluate mortality Time: 60 days
Description: number of deathMeasure: To evaluate mortality Time: 90 days
Description: Viral load by SARS-CoV-2 PCRMeasure: To evaluate viral load Time: 14 days
Description: Imatinib trough levelMeasure: To evaluate plasmatic levels of imatinib Time: 14 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports